This opportunity funds research projects that employ advanced cancer biology and preclinical models to study how radionuclide-emitted radiation affects normal tissues, tumor cells, and the tumor microenvironment. It supports multidisciplinary approaches integrating radiation biology, radiochemistry, imaging, dosimetry, and modeling to generate insights for developing new targeting strategies and optimized treatments in radiopharmaceutical therapy.
Eligible applicants include a wide range of organizations such as state, county, and city governments, educational institutions, tribal governments and organizations, nonprofits, for-profit organizations, small businesses, federal agencies, and foreign institutions.
